| For: | Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, Wu ZQ, Li Y. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. World J Gastroenterol 2004; 10(1): 136-142 [PMID: 14695785 DOI: 10.3748/wjg.v10.i1.136] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i1/136.htm |
| Number | Citing Articles |
| 1 |
Martina Kubecova, Katarina Kolostova, Daniela Pinterova, Grzegorz Kacprzak, Vladimir Bobek. Cimetidine: An anticancer drug?. European Journal of Pharmaceutical Sciences 2011; 42(5) doi: 10.1016/j.ejps.2011.02.004
|
| 2 |
Robert O. Dillman. Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 2011; 26(1) doi: 10.1089/cbr.2010.0902
|
| 3 |
Ahmad H. Ali, Laurie Hale, Bindu Yalamanchili, Mashrafi Ahmed, Marwa Ahmed, Rixin Zhou, Stephen E. Wright. The Effect of Perioperative Cimetidine Administration on Time to Colorectal Cancer Recurrence. American Journal of Therapeutics 2018; 25(4) doi: 10.1097/MJT.0000000000000547
|
| 4 |
Sanjeev Deva, Michael Jameson. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database of Systematic Reviews 2012; 2012(8) doi: 10.1002/14651858.CD007814.pub2
|
| 5 |
Bin Pan, Tao Cheng, Ke-Jun Nan, Gen-Quan Qiu, Xi-Cai Sun. Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer. World Journal of Gastroenterology 2005; 11(3): 439-442 doi: 10.3748/wjg.v11.i3.439
|
| 6 |
Phuong Linh Nguyen, Jungsook Cho. Pathophysiological Roles of Histamine Receptors in Cancer Progression: Implications and Perspectives as Potential Molecular Targets. Biomolecules 2021; 11(8) doi: 10.3390/biom11081232
|
| 7 |
Sanjeev Deva, Michael Jameson, Sanjeev Deva. Cochrane Database of Systematic Reviews. 2009; doi: 10.1002/14651858.CD007814
|
| 8 |
Anette T. Hansen Selnø, Vadim V. Sumbayev, Ulrike Raap, Bernhard F. Gibbs. Immunopharmacology and Inflammation. 2018; doi: 10.1007/978-3-319-77658-3_4
|
| 9 |
J.H. Park, D.C. McMillan, P.G. Horgan, C.S. Roxburgh. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treatment Reviews 2014; 40(1) doi: 10.1016/j.ctrv.2013.05.006
|
| 10 |
Ana Laura Torres-Román, Karla Lucero Rodríguez-Flores, Víctor Manuel Hernández-Mora, Erika Ruiz-García, Oscar Prospero-García, Alberto Guijosa, Anayansi Molina, Marcela Morales-Mulia, Michael Aschner, Abel Santamaría, Alette Ortega-Gómez. Examining the Role of Histaminergic, Orexinergic, and Cannabinergic
Systems in Redox Regulation in Gastric Adenocarcinoma. Mini-Reviews in Medicinal Chemistry 2023; 23(18) doi: 10.2174/1389557523666230221104504
|
| 11 |
Nora A. Mohamad, Tamara E. Galarza, Gabriela A. Martín. H2 antihistamines: May be useful for combination therapies in cancer?. Biochemical Pharmacology 2024; 223 doi: 10.1016/j.bcp.2024.116164
|
| 12 |
Gerben J. van der Bij, Steven J. Oosterling, Robert H. J. Beelen, Sybren Meijer, John C. Coffey, Marjolein van Egmond. The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer. Annals of Surgery 2009; 249(5) doi: 10.1097/SLA.0b013e3181a3ddbd
|
| 13 |
Hideyuki Ubukata, Hiroyuki Nagata, Takanobu Tabuchi, Satoru Konishi, Teruhiko Kasuga, Takafumi Tabuchi. Why is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcer. Gastric Cancer 2011; 14(1) doi: 10.1007/s10120-011-0005-9
|
| 14 |
WWM Gunasekara, JLAA Sachindra, MT Madhushika, PLGC Liyanage, S Lekamwasam. Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review. Journal of Oncology Pharmacy Practice 2024; 30(5) doi: 10.1177/10781552241247007
|
| 15 |
Johanna Waidhauser, Anna-Katharina Gantner, Paola Schifano, Katharina Rippel, Stefan Schiele, Tim Tobias Arndt, Gernot Müller, Julie Steinestel, Andreas Rank, Thomas Kröncke. Influence of cryoablation versus operation on circulating lymphocyte subsets in patients with early-stage renal cell carcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12596-w
|
| 16 |
Benjamin Purow. Repurposing existing agents as adjunct therapies for glioblastoma. Neuro-Oncology Practice 2016; 3(3) doi: 10.1093/nop/npv041
|
| 17 |
Tomas Koltai, Stephan J. Reshkin, Salvador Harguindey. An Innovative Approach to Understanding and Treating Cancer: Targeting pH. 2020; doi: 10.1016/B978-0-12-819059-3.00016-2
|